Philippe BERTOLINO

Dr. Philippe BERTOLINO

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2003 in Molecular Endocrinology
Verified
Journal Article
Closed access
PBPhilippe BERTOLINO
Philippe BERTOLINO
WTWei-Min Tong
Wei-Min Tong
DGDominique Galendo
Dominique Galendo
ZWZhao-Qi Wang
Zhao-Qi Wang
CZChang-Xian Zhang
Chang-Xian Zhang
Multiple endocrine neoplasia type 1 (MEN1) is a hereditary syndrome characterized by the occurrence of multiple endocrine tumors of the parathyroid, pancreas, and anterior pituitary in patients. To study tumorigenesis related to the MEN1 syndrome, we have generated Men1 knockout mice using the gene targeting approach. Heterozygous Men1 mutant mice developed the same range of major endocrine tumors as is seen in MEN1 patients, affecting the parathyroid, pancreatic islets, pituitary and adrenal glands, as well as the thyroid, and exhibiting multistage tumor progression with metastatic potential. In particular, extrapancreatic gastrinoma, pancreatic glucagonoma, and mixed hormone-producing tumors in islets were observed. In addition, there was a high incidence of gonadal tumors of endocrine origin, i.e. Leydig cell tumors, and ovary sex-cord stromal cell tumors in heterozygous Men1 mutant mice. Hormonal disturbance, such as abnormal PTH and insulin levels, was also observed in these mice. These tumors were associated with loss of heterozygosity of the wild-type Men1 allele, suggesting that menin is involved in suppressing the development of these endocrine tumors. All of these features are reminiscent of MEN1 symptoms in humans and establish heterozygous Men1 mutant mice as a suitable model for this disease.

1 December 2005 in Chest
Verified
Journal Article
Closed access
PDF file
PBPhilippe BERTOLINO
Philippe BERTOLINO
MDMartine Deckers
Martine Deckers
FLFrank Lebrin
Frank Lebrin
PDPeter Ten Dijke
Peter Ten Dijke

20 May 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
OAOlov Andersson
Olov Andersson
MKMarion Korach-André
Marion Korach-André
EREva Reissmann
Eva Reissmann
CICarlos Ibanez
Carlos Ibanez
PBPhilippe BERTOLINO
Philippe BERTOLINO
Growth/differentiation factor 3 (GDF3) is highly expressed in adipose tissue, and previous overexpression experiments in mice have suggested that it may act as an adipogenic factor under conditions of high lipid load. GDF3 has been shown to signal via the activin receptor ALK4 during embryogenesis, but functional receptors in adipose tissue are unknown. In this study, we show that Gdf3 −/− mutant mice accumulate less adipose tissue than WT animals and show partial resistance to high-fat diet-induced obesity despite similar food intake. We also demonstrate that GDF3 can signal via the ALK4-homolog ALK7 and the coreceptor Cripto, both of which are expressed in adipose tissue. In agreement with a role for ALK7 in GDF3 signaling in vivo , mutant mice lacking ALK7 also showed reduced fat accumulation and partial resistance to diet-induced obesity. We propose that GDF3 regulates adipose-tissue homeostasis and energy balance under nutrient overload in part by signaling through the ALK7 receptor.

1 May 2003 in Mechanisms of Development
Verified
Journal Article
Closed access
PBPhilippe BERTOLINO
Philippe BERTOLINO
IRIvan Radovanovic
Ivan Radovanovic
HCHuguette Casse
Huguette Casse
AAAdriano Aguzzi
Adriano Aguzzi
ZWZhao-Qi Wang
Zhao-Qi Wang
CZChang-Xian Zhang
Chang-Xian Zhang

1 May 2010 in Gastroenterology
Verified
Journal Article
Closed access
JLJieli Lu
Jieli Lu
PHPedro L. Herrera
Pedro L. Herrera
CCChristine Carreira
Christine Carreira
RBRémy Bonnavion
Rémy Bonnavion
CSChristelle Seigne
Christelle Seigne
CZChang Xian Zhang
Chang Xian Zhang

1 June 2020 in Cell Reports
Verified
Journal Article
Open access
KBKevin Berthenet
Kevin Berthenet
CFCamila Castillo Ferrer
Camila Castillo Ferrer
DFDeborah Fanfone
Deborah Fanfone
NPNikolay Popgeorgiev
Nikolay Popgeorgiev
DNDavid Neves
David Neves
GIGabriel Ichim
Gabriel Ichim
Triggering apoptosis remains an efficient strategy to treat cancer. However, apoptosis is no longer a final destination since cancer cells can undergo partial apoptosis without dying. Recent evidence shows that partial mitochondrial permeabilization and non-lethal caspase activation occur under certain circumstances, although it remains unclear how failed apoptosis affects cancer cells. Using a cancer cell model to trigger non-lethal caspase activation, we find that melanoma cancer cells undergoing failed apoptosis have a particular transcriptomic signature associated with focal adhesions, transendothelial migration, and modifications of the actin cytoskeleton. In line with this, cancer cells surviving apoptosis gain migration and invasion properties in vitro and in vivo. We further demonstrate that failed apoptosis-associated gain in invasiveness is regulated by the c-Jun N-terminal kinase (JNK) pathway, whereas its RNA sequencing signature is found in metastatic melanoma. These findings advance our understanding of how cell death can both cure and promote cancer.